Soleno Therapeutics (SLNO) Non-Current Debt (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Non-Current Debt data on file, last reported at $49.9 million in Q1 2026.

• On a quarterly basis, Non-Current Debt changed 0.07% year-over-year to $49.9 million in Q1 2026; TTM through Mar 2026 was $49.9 million, a 0.07% change from a year earlier, with the FY2025 full-year figure at $49.9 million, changed 0.07% from the prior year.
• Non-Current Debt for Q1 2026 stood at $49.9 million, roughly flat from $49.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for SLNO reached as high as $49.9 million in Q1 2026 and fell as low as $49.8 million in Q4 2024.
• Historically, Non-Current Debt has averaged $49.8 million across 3 years, with a median of $49.8 million in 2025.
• Across the five-year window, Non-Current Debt increased 0.07% in 2025 and gained 0.07% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $49.8 million in 2024, then grew by 0.07% to $49.9 million in 2025, then increased by 0.02% to $49.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $49.9 million in Q1 2026, $49.9 million in Q4 2025, and $49.9 million in Q3 2025.